Comparison of fifteen immunoassays for the measurement of serum MUC-1/CA 15-3 in breast cancer patients

Clinical Chemistry and Laboratory Medicine

Volumn 47, Issue 8, 2009, Pages 985-992

  Pichon, Marie France ^a   Brun, Gaëlle Le ^b   Hacene, Kamel ^a   Basuyau, Jean Pierre ^c   Riedinger, Jean Marc ^d   Eche, Nicole ^e   Fulla, Yvonne ^f   Charlier Bret, Natacha ^b  

^a CENTRE RENÉ HUGUENIN   (France)

^b AFSSAPS   (France)

^c CENTRE HENRI BECQUEREL   (France)

^d CENTRE GEORGES FRANÇOIS LECLERC   (France)

^e INSTITUT CLAUDIUS REGAUD   (France)

^f Institut Claudius Regaud ^*  (France)

Author keywords

Cancer antigen (CA) 15 3 immunoassays; Tumour markers

Indexed keywords

CA 15-3 ANTIGEN;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ADULT; AGED; BREAST NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; IMMUNOASSAY; MIDDLE AGED; MUCIN-1; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; RECURRENCE;

EID: 70349481810     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2009.213     Document Type: Article

References (20)

1. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochem Biophys Acta 1999;1455: 301-313
2. Hanisch FG, Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000;10:439-449
3. Basuyau JP, Blanc-Vincent MP, Bidart JM, Daver A, Deneux L, Eche N, et al. Standards, Options et Recommendations (SOR): marqueurs tumoraux sé riques du cancer du sein. Bull Cancer 2000;87:723-737
4. Hilkens J, Kroenzen V, Bonfrer JM, Bruning PF, Hilgers J, Van Eijkeren A. A sandwich radioimmunoassay for a new antigen (MAM6) present in the sera of patient with metastazied carcinomas. In: Peeters H, editor. Protides of the biological fluids. Oxford: Pergamon Press 1984; 651-653
5. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with malignant versus benign breast tumors. Hybridoma 1984;3:223-232
6. Price MR, Hudecz F, O'Sullivan C, Baldwin RW, Edwards PM, Tendler SJ. Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunology 1990;27:795-802.
7. Ceriani RL, Peterson JA, Blank EW, Lamport DT. Epitope expression on the breast epithelial mucin. Breast Cancer Res Treat 1992;24:103-113
8. Briggs S, Price MR, Tendler SJ. Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes. Eur J Cancer 1993;29:230-237
9. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, et al. Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumor Biology 1998;19(Suppl 1):1-20.
10. Cohen R, Zucchelli GC, Fraysse M, Pilo A, Rigault MY, Grillet S, et al. Oncocheck: an international external quality assessment scheme for immunoassays of tumor markers. Nucl Med Biol 1994;21:483-493
11. Slev RS, Rawlins ML, Roberts WL. Performance characteristics of seven automated CA 15-3 assays. Am J Clin Pathol 2006;125:752-757
12. Stern P, Bartos V, Vavrova J, Bezdickova D, Pechova M, Uhrova J, et al. Comparability of eight immunoassay procedures for the determination of CA 15-3 related markers. Clin Chem Lab Med 2003;41:1087-1094
13. Agence Francaise de Sé curité Sanitaire des Produits de ̧Santé (AFSSAPS). Rapport du controle du marché des DMDIV de MUC-1/CA 15-23 http://agmed.sante.gouv.fr/ htm/10/dm/sdm/rapport-controle- dmdiv-muc.pdf.
14. Fédé ration Nationale des Centres de Lutte Contre Le Cancer. Standards, Options et Recommandations: cancers du sein infiltrants non mé tastatiques, v.2 revised, Montrouge: John Libbey Eurotext, 2001:369 pp.
15. Stenman UH. Immunoassay standardization: is it possible, who is responsible, who is capable? Clin Chem 2001;47:815-820
16. Hubl W, Demant T, Albrecht S, Bewarder N, Grunow G, Keller, et al. A multi-center quality control study of different CA 15-3 immunoassays. Clin Lab 2005;51:641-645
17. Van Dalen A. Analytical requirements and standardization of CA 15-3. Scand J Clin Lab Invest 1995;221(Suppl): 102-104
18. Hilgers J, Von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P. Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists. Scand J Clin Lab Invest 1995;55(Suppl 221):81-86
19. Klee G. MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA 15-3, CA 27-29, BR). Are they measuring the same antigen. Arch Pathol Lab Med 2004;128:1131-1135
20. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-577